Integrated Biotherapeutics, Inc.

US Government As Represented by the Secretary of the Army

Emergent Virology LLC

Tam Nguyen

Kelly Lyn Warfield

Mohammad Javad Aman

Rajan Prasad Adhikari

Hatice Karauzum

Hitesh Batra

Sina Bavari

Raju A Penmasta

Urban Ramstedt

Rick Gussio

Sergey Shulenin

Rekha G Panchal

Jawad Sarwar

Sathya Venkataramani

Ann Hermone

The present application provide novel iminosugars and their use in treatment of viral infections, such as Dengue infection and Influenza A infection. The present inventors discovered certain deoxynojirimycin derivatives may be effective against one or more viruses, which may be, for example, a Dengue virus and/or a virus belonging to the Orthomyxoviridae family, such as an Influenza A virus. In particular, such deoxynojirimycin derivatives may be useful for treating a disease or condition caused by or associated with one or more viruses. In certain embodiments, the deoxynojirimycin derivatives may increase a survival rate or probability for a subject infected with one or more viruses, which may be, for example, a Dengue virus and/or a virus belonging to the Orthomyxoviridae family, such as an Influenza A virus.

Deoxynojirimycin derivatives and methods of their using

The present disclosure provides immunogenic compositions useful in prevention and treatment ofinfection. In particular, the disclosure provides methods of inducing an immune response against a panton-valentine leukocidin (PVL)-expressing, methods of preventing or treatinginfections, and composition for preventing or treatinginfections.

Immunogenic composition comprising Panton-Valentine Leukocidin (PVL) derived polypeptides

The present invention provides immunogenic compositions useful in prevention and treatment ofinfection. In particular, the present invention provides methods of inducing an immune response against an alpha-hemolysin-expressing, methods of preventing or treatinginfections, and composition for preventing or treatinginfections.

Immunogenic composition comprising alpha-hemolysin oligopeptides

Disclosed herein is a pharmacophore model for inhibiting anthrax lethal factor protease activity which comprises a first aromatic center A, a second aromatic center B, a first polar center C, a second polar center D, a third polar center E, and a neutral linker F. Also disclosed are small molecules fitting the pharmacophore model and compositions and methods of using thereof.

Inhibition of anthrax lethal factor protease

Growing community of inventors

Gaithersburg, MD, United States of America

Tam Nguyen